A cross-sectional study of 128 individuals infected with human immunodeficiency virus type 1 (HIV-1) was conducted to determine the correlation of reverse transcriptase-inhibiting (RTI) antibody to clinical disease. Thirty-two individuals were studied in each of four clinical groups: asymptomatic individuals, those with persistent generalized Iymphadenopathy, those with acquired immune deficiency syndrome (AIDS)-related complex, and those with AIDS. Our study showed that 78% of asymptomatic individuals, 53% of those with persistent generalized Iymphadenopathy, 50% of those with AIDS-related complex, and only 25% of those with AIDS have RTI antibody. Concurrent measurement of measles antibody level was used as an indicator of the immune status of these individuals. Measles antibody did not decline in persons with clinical disease, but asymptomatic individuals had lower antibody titers, possibly due to hypergammaglobulinemia associated with advanced HIV infection. These results indicate that more HIV-infected asymptomatic individuals than symptomatic individuals have RTI antibody. This suggests either that the RTI antibody level decreases with the progression of disease in HIV infection or that symptomatic individuals do not produce RTI antibody. The presence or absence of RTI antibody can thus be used as a marker of advanced disease.
Reverse transcriptase (RT) is an enzyme residing in the core of the human immunodeficiency virus (HIV) and is essential for viral replication (11, 12) . RT is composed of two proteins (p66/p51), and antibody to these proteins is present in approximately 80 to 98% of HIV-infected individuals (1, 3, 10, 13 ). An antibody that inhibits RT enzyme activity is also found in most HIV-infected asymptomatic individuals and appears not to be directly related to the presence of antibodies against p66/p5l, since not all individuals with the p66/p51 antibodies have RT-inhibiting (RTI) antibody (10) . There is much interest in the RTI antibody, since it has been shown previously, with a small number of individuals, to be absent during disease development in HIV infection (2, 7) . In contrast, studies of p66/p51 antibody showed that lit did not vary in different clinical stages of the disease (3).
The production of RTI antibody is not common. There have been reports of only a few other naturally occurring animal retrovirus infections with this antibody: G-murine leukemia virus in AKR mice (4), natural bovine leukemia virus infection in cattle (14) , and natural exposure of cats to feline leukemia virus (5) . The production of RTI antibody to feline leukemia virus was associated with less detectable virus, and absence of the antibody was accompanied by viremia in cats (5) . Similar results were observed with HIV infection in humans (10) .
We studied 128 HIV-infected individuals to examine the correlation of RTI antibody to clinical status and to determine the possible use of this antibody as a marker for advanced HIV infection. at 37°C for 18 to 22 h as described by Lee et al. (8) . The amount of [3H]dTMP incorporated into DNA product was counted in a liquid scintillation spectrometer, and the percent inhibition of RT was calculated. Positive inhibition of RT is defined as a 250% decrease in enzyme activity compared with the activity of control serum of a seronegative individual. For each RTI assay, a known RTI-positive serum and a known RTI-negative serum served as controls. Measles antibody titer. Immune status of each individual was also evaluated by measuring measles antibody levels. Purified IgG samples were diluted twofold (starting with a dilution of 1:80) and tested. Measles antibody was determined by using commercially available enzyme-linked immunosorbent assay kits (M. A. Bioproducts). Instructions provided with the kits were followed.
MATERIALS AND METHODS
Statistical analysis. The results of the RTI antibody and the measles antibody level assays in the four groups were compared by the Pearson chi-square test.
RESULTS
The presence of RTI antibody in the sera of 32 individuals in each of the four clinical groups is shown in Table 1 . In the asymptomatic group, 25 (78%) persons had positive enzyme inhibition. In the AIDS group, only 8 (25%) had positive inhibition. Statistical analysis showed a highly significant (P < 0.0001) overall difference among the four groups, and the test for linear trend (asymptomatic to AIDS) also showed a highly significant (P < 0.0001) difference. Pairwise contrast showed a significant difference only between the asymptomatic and the AIDS groups (P = 0.01). We have previously shown that HIV seronegative individuals do not show any RTI antibody activity (10) . Three representative RTI antibody dilution curves are shown in Fig. 1 to demonstrate antibody specificity. These curves delineate an inverse relationship between percent inhibition and serum dilution. The geometric mean measles antibody titers of the 32 individuals studied in each of the four clinical groups are as follows: asymptomatic group, 51; PGL group, 226; ARC group, 121; and AIDS group, 161. These titers are expressed as the mean anti-log2 of the highest serum dilution with antibody. For the calculation of the geometric mean, a titer of <1:80 was assigned a value of 40. The Kruskal-Wallis test showed overall differences among groups. The levels of measles antibody did not decrease in the AIDS group. Posttest Helmert contrasts showed that asymptomatic individuals had significantly lower measles antibody titers than individuals with PGL, ARC, or AIDS (P < 0.0001). There were no other significant differences. sence of RTI antibody and the development of AIDS. This study confirms similar findings reported earlier (2, 7). These are interesting observations, since it has been reported that levels of RT (p66/p5l) antibody do not correlate with clinical disease (3). The present study further substantiates that p66/p5l antibody does not directly measure the RTI antibody. Sano et al. (10) have compared the Western blots (immunoblots) of individuals producing RTI with the Western blots of those lacking RTI antibody. They found a wide variation in p66/p51 antibody levels between the two groups, with no correlation to RTI. The limitation of our study, which looked at a cross-sectional pattern of RTI antibody among different groups, is that antibody response may vary from person to person. It would be important to monitor the same individual in series from the time of seroconversion to the development of PGL, ARC, or AIDS and to evaluate the RTI antibody pattern of the individual.
Our findings in the present study show no statistical difference between RTI antibody in the ARC and PGL groups. This could be explained by the fact that there is considerable overlapping in the clinical picture of these two groups. Similar findings were noted by Chattejee et al. (2) .
We feel that the decreased presence of RTI with advancing clinical disease is not mere loss of antibody due to an increasing viral antigen load. Data (10) . Similar results were also seen in cats infected with feline leukemia virus (5) . Further proof of this concept might be worked out in an in vitro model.
The importance of RTI antibody appears to be twofold. First, the presence of the RTI antibody could be used as a prognostic indicator, since studies have shown that its absence is associated with clinical AIDS. This can be further substantiated by longitudinal studies (manuscript in preparation). Secondly, RTI antibody may be a protective antibody. This is an attractive idea, because RTI antibody may then be useful in the treatment of or in the design of a vaccine against HIV. RTI antibody of infected individuals might be boosted in an effort to suppress the progression of the disease, a concept originally proposed by Salk (9) .
